Home>>Analytical Standards>>HU-331

HU-331 (Synonyms: Cannabidiolquinone)

Catalog No.GC41298

The endocannabinoids present a rich system of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation.

Products are for research use only. Not for human use. We do not sell to patients.

HU-331 Chemical Structure

Cas No.: 137252-25-6

Size Price Stock Qty
1mg
$82.00
In stock
5mg
$371.00
In stock
10mg
$658.00
In stock
25mg
$1,439.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

The endocannabinoids present a rich system of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation. HU-331 is a hydroxylquinone cannabidiol analog that exhibits potent antineoplastic activity on a variety of human cancer cell lines. It effectively inhibits the growth of human Raji and Jurkat lymphoma cells in vitro with an EC50 of approximately 0.2 µg/ml and an EC80 of 1.56 µg/ml. HU-331 also inhibits the growth of HT-29 colon carcinoma cells, which have been inoculated into nude mice, by more than 50% at a dose of 5 mg/kg.

Reviews

Review for HU-331

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for HU-331

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.